Adrenocortical tumors and insulin resistance: What is the first step?

Barbara Altieri, Giacomo Tirabassi, Silvia Della Casa, Cristina L. Ronchi, Giancarlo Balercia, Francesco Orio, Alfredo Pontecorvi, Annamaria Colao, Giovanna Muscogiuri*

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

12 Citazioni (Scopus)


The pathogenetic mechanisms underlying the onset of adrenocortical tumors (ACTs) are still largely unknown. Recently, more attention has been paid to the role of insulin and insulin-like growth factor (IGF) system on general tumor development and progression. Increased levels of insulin, IGF-1 and IGF-2 are associated with tumor cell growth and increased risk of cancer promotion and progression in patients with type 2 diabetes. Insulin resistance and compensatory hyperinsulinemia may play a role in adrenal tumor growth through the activation of insulin and IGF-1 receptors. Interestingly, apparently non-functioning ACTs are often associated with a high prevalence of insulin resistance and metabolic syndrome. However, it is unclear if ACT develops from a primary insulin resistance and compensatory hyperinsulinemia or if insulin resistance is only secondary to the slight cortisol hypersecretion by ACT. The aim of this review is to summarize the current evidence regarding the relationship between hyperinsulinemia and adrenocortical tumors.
Lingua originaleEnglish
pagine (da-a)2785-2794
Numero di pagine10
RivistaInternational Journal of Cancer
Stato di pubblicazionePubblicato - 2016


  • Adrenal Cortex Neoplasms
  • Adrenal Gland Neoplasms
  • Animals
  • Cancer Research
  • Humans
  • Hydrocortisone
  • IGF-1R
  • Insulin
  • Insulin Resistance
  • Medicine (all)
  • Oncology
  • adrenocortical tumor
  • cortisol
  • insulin receptor
  • insulin resistance


Entra nei temi di ricerca di 'Adrenocortical tumors and insulin resistance: What is the first step?'. Insieme formano una fingerprint unica.

Cita questo